2.1 Diagnostics
Fischer
Fontes
Houston
Klion
Lammie†
Working Group Chairperson and/or Report Section Author.
Melrose
Noordin
Ottesen
Ramzy
Ravindran
Weil
Weerasooriya
Williams
2.2a Intervention Tools— Chemotherapy
Bradley†
Brandling-Bennett
Brown
Buettner
Coyne
Hoerauf
Kron
Lazdins-Helds
McCall
Prichard
Rajan
2.2b Clinical Drug Trials
Alexander
Basáñez
Bradley
Brown
Coyne
Kazura
Kron
Kumaraswami†
Lazdins-Helds
Mand
McCall
Noordin
Ramzy
Saah
Stolk
Taylor
Weerasooriya
2.4 Program Implementation
Bagnall
Balducci-Silano
Biswas
Dadzie
Ehrenberg
Kyelem
Lammie
Malecela-Lazaro†
Prichard
Richards
Streit
Twum-Danso†
2.5 Monitoring and Evaluation
Bockarie
Burkot
Das
El Setouhy
Fischer
Fontes
Gyapong†
Habbema
Houston
Ichimori
Lam
Mathieu
Melrose
Ottesen
Sun
Weil
Williams
2.6 Epidemiology, Parasite Biology, Modeling
Alexander
Balducci-Silano
Basáñez†
Biswas
Dadzie†
Ehrenberg
El Setouhy
Gyapong
Habbema
Kyelem
Lam
Lustigman
Mathieu
Richards†
Stolk
Sun
Twum-Danso
2.8 Health Systems‡
Compiled by L. Barrett and D. McFarland based on a 1/2004 meeting in Crewe, United Kingdom (see attendees in Annex 3B).
3.1 Pathogenesis
Abraham
Addiss
Dreyer
Kazura†
King†
Klei
Kumaraswami
Mackenzie
Malecela
Mand
Noroes
Nutman
Ryan
Seim
Shenoy
Steel
Taylor
Additional contributors were C. Curtis (London, United Kingdom); D. Durrheim (Townsville, Australia); E. Michael (London, United Kingdom); S. P. Pani (Pondicherry, India); A. Rocha (Recife, Brazil); P. Simonsen (Copenhagen, Denmark); S. Townson (London, United Kingdom).